Autologous Anti-CD20CAR-CD28-4-1BB-CD3zeta T-lymphocytes MB-106

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of autologous T-lymphocytes that have been transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) cluster of differentiation 20 (CD20) and coupled to the co-stimulatory signaling domain CD28, the signaling domain of 4-1BB (CD137), and the zeta chain of the T-cell receptor (TCR)/CD3 complex (CD3zeta), with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-CD20CAR-CD28-4-1BB-CD3zeta T-lymphocytes MB-106 specifically recognize and kill CD20-expressing tumor cells. The CD20 antigen, a non-glycosylated B-cell specific surface phosphoprotein that plays a role in the differentiation of B-cells into plasma cells, is overexpressed in B-cell lineage malignancies and certain melanoma cell subpopulations.

**Synonyms:** - Autologous Anti-CD20 CAR-T Cells MB-106 - Autologous Anti-CD20CAR-CD28-4-1BB-CD3zeta-expressing T-lymphocytes MB-106 - CD20-targeted Autologous CAR-T Cells MB-106 - MB 106 - MB-106 - MB106